the presence de novo of high proportions of p-170-expressing cells in another still untreated patient and in a further individual with resistance to dexamethasone and interferon ( not associated with mdr ) warrants systematic analysis of p-170 expression prior to therapy to determine its clinical implications for response to mdr-associated drugs as combined in the vad regimen .
C0011777
dexamethasone
C1948034
vad regimen